Cargando…

Heart Failure and MEF2 Transcriptome Dynamics in Response to β-Blockers

Myocyte Enhancer Factor 2 (MEF2) mediates cardiac remodelling in heart failure (HF) and is also a target of β-adrenergic signalling, a front-line treatment for HF. We identified global gene transcription networks involved in HF with and without β-blocker treatment. Experimental HF by transverse aort...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tobin, S. W., Hashemi, S., Dadson, K., Turdi, S., Ebrahimian, K., Zhao, J., Sweeney, G., Grigull, J., McDermott, J. C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493616/ https://www.ncbi.nlm.nih.gov/pubmed/28667250 http://dx.doi.org/10.1038/s41598-017-04762-x

Ejemplares similares

Heart disease: recruitment of MEF2 activity by β−blockers wards off cardiomyocyte death
por: Hashemi, S, et al.
Publicado: (2015)

Pro-survival function of MEF2 in cardiomyocytes is enhanced by β-blockers
por: Hashemi, S, et al.
Publicado: (2015)

The MEF2A transcription factor interactome in cardiomyocytes
por: Moustafa, Amira, et al.
Publicado: (2023)

Global MEF2 target gene analysis in cardiac and skeletal muscle reveals novel regulation of DUSP6 by p38MAPK-MEF2 signaling
por: Wales, Stephanie, et al.
Publicado: (2014)

β blockers for heart failure
por: Hoes, Arno W
Publicado: (2016)

Temporal and Molecular Analyses of Cardiac Extracellular Matrix Remodeling following Pressure Overload in Adiponectin Deficient Mice
por: Dadson, Keith, et al.
Publicado: (2015)

The Use of β-Blockers in Heart Failure with Reduced Ejection Fraction
por: Masarone, Daniele, et al.
Publicado: (2021)

β(1)-Blockers Enhance Inotropy of Endogenous Catecholamines in Chronic Heart Failure
por: Feuerstein, Thomas J., et al.
Publicado: (2021)

Suboptimal Dosing of β-Blockers in Chronic Heart Failure: A Missed Opportunity?
por: McGinlay, Melanie, et al.
Publicado: (2022)

β-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature
por: DiNicolantonio, James J, et al.
Publicado: (2015)

Underuse of β-blockers in heart failure and chronic obstructive pulmonary disease
por: Lipworth, Brian, et al.
Publicado: (2016)

Differences in MEF2 and NFAT Transcriptional Pathways According to Human Heart Failure Aetiology
por: Cortés, Raquel, et al.
Publicado: (2012)

β-AR Blockers Suppresses ER Stress in Cardiac Hypertrophy and Heart Failure
por: Ni, Li, et al.
Publicado: (2011)

A meta-analysis of the effects of β-adrenergic blockers in chronic heart failure
por: Zhang, Xiaojian, et al.
Publicado: (2016)

Chronic obstructive pulmonary disease and β‐blocker treatment in Asian patients with heart failure
por: Kubota, Yoshiaki, et al.
Publicado: (2017)

Beta-blockers and mechanical dyssynchrony in heart failure assessed by radionuclide ventriculography
por: Jones, K. A., et al.
Publicado: (2022)

Adrenergic receptor genotype influences heart failure severity and β-blocker response in children with dilated cardiomyopathy
por: Reddy, Sushma, et al.
Publicado: (2015)

Relationships among achieved heart rate, β-blocker dose and long-term outcomes in patients with heart failure with atrial fibrillation
por: Miller, Robert J H, et al.
Publicado: (2016)

Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis
por: Chatterjee, Saurav, et al.
Publicado: (2013)

Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis
Publicado: (2013)

Beta-Blockers and Oxidative Stress in Patients with Heart Failure
por: Nakamura, Kazufumi, et al.
Publicado: (2011)

New advances in beta-blocker therapy in heart failure
por: Barrese, Vincenzo, et al.
Publicado: (2013)

MEF2C repressor variant deregulation leads to cell cycle re-entry and development of heart failure
por: Pereira, Ana Helena M., et al.
Publicado: (2020)

The effect of beta-blockers in acute heart failure according to heart rate
por: Kim, Hyun-Jin, et al.
Publicado: (2021)

Comparison of ivabradine plus β-blockers versus β-blocker therapy only
por: Aalbers, J
Publicado: (2010)

β‐Blockers and 1‐Year Postdischarge Mortality for Heart Failure and Reduced Ejection Fraction and Slow Discharge Heart Rate
por: Park, Jin Joo, et al.
Publicado: (2019)

Evaluation of β-blocker Dose Optimisation Among Patients Attending Heart Failure Clinic at Sarawak Heart Centre, Malaysia
por: Wong, Yii Ching, et al.
Publicado: (2021)

Search for HRV-parameters that detect a sympathetic shift in heart failure patients on β-blocker treatment
por: Zhang, Yanru, et al.
Publicado: (2013)

β-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction
por: Dondo, Tatendashe B., et al.
Publicado: (2017)

Everolimus Use for Intolerance or Failure of Baseline Immunosuppression in Adult Heart and Lung Transplantation
por: Kelsh, Shelby E., et al.
Publicado: (2018)

Genetic Polymorphisms in ADRB2 and ADRB1 Are Associated with Differential Survival in Heart Failure Patients Taking β-Blockers
por: Guerra, Leonardo A., et al.
Publicado: (2022)

Poor tolerance of beta-blockers by elderly patients with heart failure
por: Yanagisawa, Satoshi, et al.
Publicado: (2010)

Beta Blockers in Heart Failure: More Evidence for an Old Friend
por: Baek, Sang Hong
Publicado: (2018)

Treatment optimization of beta-blockers in chronic heart failure therapy
por: Niriayo, Yirga Legesse, et al.
Publicado: (2020)

ADRB2 polymorphism Arg16Gly modifies the natural outcome of heart failure and dictates therapeutic response to β-blockers in patients with heart failure
por: Huang, Jin, et al.
Publicado: (2018)

Redefining β-blocker response in heart failure patients with sinus rhythm and atrial fibrillation: a machine learning cluster analysis
por: Karwath, Andreas, et al.
Publicado: (2021)

β1 Adrenergic Receptor Polymorphisms and Heart Failure: A Meta-Analysis on Susceptibility, Response to β-Blocker Therapy and Prognosis
por: Liu, Wen-Nan, et al.
Publicado: (2012)

β blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study
por: Puymirat, Etienne, et al.
Publicado: (2016)

β blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study
Publicado: (2016)

β-blocker and 1-year outcomes among patients hospitalized for heart failure with mid-range ejection fraction
por: Wang, Bin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e483iv9b5lhbf64hbr8ddirc57